Cargando…

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinrich, B, Klein, J, Delic, M, Goepfert, K, Engel, V, Geberzahn, L, Lusky, M, Erbs, P, Preville, X, Moehler, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422459/
https://www.ncbi.nlm.nih.gov/pubmed/28496337
http://dx.doi.org/10.2147/OTT.S126320
_version_ 1783234781386899456
author Heinrich, B
Klein, J
Delic, M
Goepfert, K
Engel, V
Geberzahn, L
Lusky, M
Erbs, P
Preville, X
Moehler, M
author_facet Heinrich, B
Klein, J
Delic, M
Goepfert, K
Engel, V
Geberzahn, L
Lusky, M
Erbs, P
Preville, X
Moehler, M
author_sort Heinrich, B
collection PubMed
description Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are genetically modified by secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) or transforming 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). We compared their properties to kill tumor cells and induce an immunogenic type of cell death in a human melanoma cell model using SK29-MEL melanoma cells. Their influence on human immune cells, specifically regarding the activation of dendritic cells (DCs) and the interaction with the autologous cytotoxic T lymphocyte (CTL) clone, was investigated. Melanoma cells were infected with either JX-GFP or TG6002 alone or in combination with 5-FC and 5-FU. The influence of viral infection on cell viability followed a time- and multiplicity of infection dependent manner. Combination of virus treatment with 5-FU resulted in stronger reduction of cell viability. TG6002 in combination with 5-FC did not significantly strengthen the reduction of cell viability in this setting. Expression of calreticulin and high mobility group 1 protein (HMGB1), markers of immunogenic cell death (ICD), could be detected after viral infection. Accordingly, DC maturation was noted after viral oncolysis. DCs presented stronger expression of activation and maturation markers. The autologous CTL clone IVSB expressed the activation marker CD69, but viral treatment failed to enhance cytotoxicity marker. In summary, vaccinia viruses JX-GFP and TG6002 lyse melanoma cells and induce additional immunostimulatory effects to promote antitumor immune response. Further investigation in vivo is needed to consolidate the data.
format Online
Article
Text
id pubmed-5422459
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54224592017-05-11 Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes Heinrich, B Klein, J Delic, M Goepfert, K Engel, V Geberzahn, L Lusky, M Erbs, P Preville, X Moehler, M Onco Targets Ther Original Research Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are genetically modified by secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) or transforming 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). We compared their properties to kill tumor cells and induce an immunogenic type of cell death in a human melanoma cell model using SK29-MEL melanoma cells. Their influence on human immune cells, specifically regarding the activation of dendritic cells (DCs) and the interaction with the autologous cytotoxic T lymphocyte (CTL) clone, was investigated. Melanoma cells were infected with either JX-GFP or TG6002 alone or in combination with 5-FC and 5-FU. The influence of viral infection on cell viability followed a time- and multiplicity of infection dependent manner. Combination of virus treatment with 5-FU resulted in stronger reduction of cell viability. TG6002 in combination with 5-FC did not significantly strengthen the reduction of cell viability in this setting. Expression of calreticulin and high mobility group 1 protein (HMGB1), markers of immunogenic cell death (ICD), could be detected after viral infection. Accordingly, DC maturation was noted after viral oncolysis. DCs presented stronger expression of activation and maturation markers. The autologous CTL clone IVSB expressed the activation marker CD69, but viral treatment failed to enhance cytotoxicity marker. In summary, vaccinia viruses JX-GFP and TG6002 lyse melanoma cells and induce additional immunostimulatory effects to promote antitumor immune response. Further investigation in vivo is needed to consolidate the data. Dove Medical Press 2017-05-02 /pmc/articles/PMC5422459/ /pubmed/28496337 http://dx.doi.org/10.2147/OTT.S126320 Text en © 2017 Heinrich et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Heinrich, B
Klein, J
Delic, M
Goepfert, K
Engel, V
Geberzahn, L
Lusky, M
Erbs, P
Preville, X
Moehler, M
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
title Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
title_full Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
title_fullStr Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
title_full_unstemmed Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
title_short Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
title_sort immunogenicity of oncolytic vaccinia viruses jx-gfp and tg6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic t lymphocytes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422459/
https://www.ncbi.nlm.nih.gov/pubmed/28496337
http://dx.doi.org/10.2147/OTT.S126320
work_keys_str_mv AT heinrichb immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT kleinj immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT delicm immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT goepfertk immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT engelv immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT geberzahnl immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT luskym immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT erbsp immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT previllex immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes
AT moehlerm immunogenicityofoncolyticvacciniavirusesjxgfpandtg6002inahumanmelanomainvitromodelstudyingimmunogeniccelldeathdendriticcellmaturationandinteractionwithcytotoxictlymphocytes